The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or inhalation. A nasal COVID-19 vaccine, developed using technology from Washington ...

ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

To date Mesa received $4.5 million in One Arizona settlement funds. The city will give $1 million to nonprofits working to ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

As a nurse, I’ve seen how the virus can cause serious health complications. Check out the following items to keep on hand to ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...